US · FDMT · BIOTECHNOLOGY
4D Molecular Therapeutics, Inc. (FDMT) intrinsic value and stock valuation
$10.23as of 2026-11-21 · Mkt cap 537.4M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
4D Molecular Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values FDMT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FDMT’s statements →
4D Molecular Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lexicon Pharmaceuticals, Inc. (LXRX) $1.53
- Omeros Corporation (OMER) $13.21
- REGENXBIO Inc. (RGNX) $7.16
- Prothena Corporation plc (PRTA) $8.22
- Compass Therapeutics, Inc. (CMPX) $0.69
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Bicycle Therapeutics plc (BCYC) $2.90
- ADC Therapeutics S.A. (ADCT) $1.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $85.2M | $40K | $20.7M | $3.13M | $18M |
| Operating income | -$-159.55M | -$-187.84M | -$-112.87M | -$-110.03M | -$-71.33M |
| Net income | -$-140.11M | -$-160.87M | -$-100.84M | -$-107.49M | -$-71.32M |
| EPSd | -$-2.42M | -$-2.98M | -$-2.58M | -$-3.32M | -$-2.57M |
| Operating cash flow | -$-109.08M | -$-134.59M | -$-75.79M | -$-86.69M | -$-69.13M |
| Capital expenditure | -$-540K | -$-3.79M | -$-2.77M | -$-11.54M | -$-9.11M |
| Free cash flow | -$-109.08M | -$-138.37M | -$-78.56M | -$-98.22M | -$-78.24M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.9M | $353.5M |
| Total debt | $21.4M | $24.6M | $14.7M | $16.1M | $16.5M |
| Net debt | -$-38.83M | -$-124.73M | -$-234.44M | -$-36.23M | -$-136.55M |
| Total equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
| Cash and short-term investments | $402.7M | $424.9M | $288.2M | $213.6M | $247.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $85.2M | $40K | $20.7M | $3.13M | $18M |
| Cost of revenue | $7.62M | $141.3M | $97.1M | $80.3M | $61.4M |
| Gross profit | $77.6M | -$-141.26M | -$-76.37M | -$-77.12M | -$-43.32M |
| Research and development expenses | $195.7M | $141.3M | $97.1M | $80.3M | $61.4M |
| Selling, general and administrative expenses | $49.1M | $46.6M | $36.5M | $32.9M | $28M |
| Other expenses | -$-7.62M | -$-141.3M | -$-97.1M | -$-80.25M | -$-61.36M |
| Operating expenses | $237.1M | $46.6M | $36.5M | $32.9M | $28M |
| Cost and expenses | $244.8M | $187.9M | $133.6M | $113.2M | $89.4M |
| Interest income | $19.5M | $27.1M | $12.2M | $2.57M | $140K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $7.62M | $6.71M | $4.2M | $2.4M | $1.52M |
| Ebitda | -$-132.48M | -$-154.16M | -$-96.63M | -$-105.09M | -$-69.79M |
| Operating income | -$-159.55M | -$-187.84M | -$-112.87M | -$-110.03M | -$-71.33M |
| Total other income/expenses, net | $19.4M | $27M | $12M | $2.54M | $20K |
| Income before tax | -$-140.11M | -$-160.87M | -$-100.84M | -$-107.49M | -$-71.32M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-140.11M | -$-160.87M | -$-100.84M | -$-107.49M | -$-71.32M |
| Weighted average shares outstanding | $57.9M | $53.9M | $39.1M | $32.4M | $27.7M |
| Weighted average diluted shares outstanding | $57.9M | $53.9M | $39.1M | $32.4M | $27.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $402.7M | $424.9M | $288.2M | $213.6M | $247.8M |
| Net receivables | $0.00 | $0.00 | $0.00 | $700K | $50K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $413.1M | $434.9M | $296.6M | $220.5M | $256.3M |
| Property, plant and equipment, net | $33M | $40.6M | $31.7M | $35.4M | $29M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $111.4M | $80.6M | $11M | $4.91M | $67.7M |
| Total non-current assets | $153.6M | $125.5M | $43.3M | $41.3M | $97.2M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.9M | $353.5M |
| Accounts payable | $11.2M | $4.39M | $3.52M | $3.32M | $4.76M |
| Short-term debt | $5.59M | $5.64M | $3.15M | $5.31M | $1.23M |
| Deferred revenue | $360K | $260K | $270K | $880K | $2.6M |
| Total current liabilities | $44M | $29.2M | $19M | $15.7M | $16.3M |
| Long-term debt | $15.8M | $19M | $11.5M | $13.5M | $15.2M |
| Deferred revenue, non-current | $740K | $1.06M | $970K | $1.08M | $2.49M |
| Total non-current liabilities | $17.1M | $20.6M | $13.1M | $14.8M | $18M |
| Capital lease obligations | $21.4M | $24.6M | $14.7M | $16.1M | $16.5M |
| Total liabilities | $61.1M | $49.8M | $32.1M | $30.5M | $34.4M |
| Common stock | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-716.3M | -$-576.2M | -$-415.33M | -$-314.49M | -$-207M |
| Accumulated other comprehensive income (loss) | $730K | $230K | $20K | -$-1.2M | -$-420K |
| Total equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
| Total investments | $453.8M | $356.1M | $50.1M | $166.1M | $162.4M |
| Total debt | $21.4M | $24.6M | $14.7M | $16.1M | $16.5M |
| Net debt | -$-38.83M | -$-124.73M | -$-234.44M | -$-36.23M | -$-136.55M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-140.11M | -$-160.87M | -$-100.84M | -$-107.49M | -$-71.32M |
| Depreciation and amortization | $7.62M | $6.71M | $5.75M | $3.88M | $3.02M |
| Stock-based compensation | $22M | $26.1M | $19.7M | $17.1M | $13.8M |
| Change in working capital | $6.17M | $540K | $630K | -$-1.34M | -$-15.53M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $50K | $1.44M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-4.54M |
| Accounts payable | $6.77M | $870K | $900K | -$-1.64M | $2.29M |
| Net cash provided by operating activities | -$-109.08M | -$-134.59M | -$-75.79M | -$-86.69M | -$-69.13M |
| Investments in property, plant and equipment | -$-540K | -$-3.79M | -$-2.77M | -$-11.54M | -$-9.11M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $9.11M |
| Net cash used for investing activities | -$-92.97M | -$-302.44M | $115.7M | -$-17.05M | -$-172.68M |
| Common stock issued | $113M | $331.4M | $148.3M | $3.08M | $114.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $113M | $337.3M | $156.8M | $3.08M | $118.1M |
| Net change in cash | -$-89.09M | -$-99.77M | $196.8M | -$-100.65M | -$-123.72M |
| Cash at end of period | $60.2M | $149.3M | $249.1M | $52.4M | $153M |
| Operating cash flow | -$-109.08M | -$-134.59M | -$-75.79M | -$-86.69M | -$-69.13M |
| Capital expenditure | -$-540K | -$-3.79M | -$-2.77M | -$-11.54M | -$-9.11M |
| Free cash flow | -$-109.08M | -$-138.37M | -$-78.56M | -$-98.22M | -$-78.24M |
Line items
Line items
Line items
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
- CEO
- David H. Kirn
- Employees
- 196
- Beta
- 2.69
Explore
Frequently asked questions
What is the intrinsic value of 4D Molecular Therapeutics, Inc. (FDMT)?
InvestorsCraft does not currently publish an intrinsic value for FDMT. How the IC value is calculated.
Is FDMT undervalued?
InvestorsCraft does not publish an undervaluation signal for FDMT at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.